DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K. SIGN Study Group.
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Anticancer Drugs 2006;
17: 401-9
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.